REVENUE (Tables)

9 Months Ended

Jul. 31, 2023

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:



	Three Months Ended July 31,
	2023								2022
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	312	$	159	$	196	$	667	$	336	$	147	$	188	$	671
Europe	217		108		107		432		210		94		103		407
Asia Pacific	398		129		46		573		473		118		49		640
Total	$	927	$	396	$	349	$	1,672	$	1,019	$	359	$	340	$	1,718



	Nine Months Ended July 31,
	2023								2022
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	954	$	467	$	609	$	2,030	$	974	$	416	$	577	$	1,967
Europe	701		309		311		1,321		678		289		314		1,281
Asia Pacific	1,273		388		133		1,794		1,239		366		146		1,751
Total	$	2,928	$	1,164	$	1,053	$	5,145	$	2,891	$	1,071	$	1,037	$	4,999

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


	Three Months Ended				Nine Months Ended
	July 31,				July 31,
	2023		2022		2023		2022
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	592	$	643	$	1,843	$	1,834
Chemicals and Advanced Materials	378		389		1,162		1,097
Diagnostics and Clinical	241		234		730		718
Food	151		151		472		446
Academia and Government	146		139		451		426
Environmental and Forensics	164		162		487		478
Total	$	1,672	$	1,718	$	5,145	$	4,999

Revenue by Type
Instrumentation	$	643	$	737	$	2,091	$	2,074
Non-instrumentation and other	1,029		981		3,054		2,925
Total	$	1,672	$	1,718	$	5,145	$	4,999

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2023:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2022	$	557
Net revenue deferred in the period	438
Revenue recognized that was included in the contract liability balance at the beginning of the period	(368)
Change in deferrals from customer cash advances, net of revenue recognized	(24)

Currency translation and other adjustments	19
Ending balance as of July 31, 2023	$	622